

CITATION REPORT

List of articles citing

Extrahepatic metabolism of drugs in humans

DOI: 10.2165/00003088-199426020-00007
Clinical Pharmacokinetics, 1994, 26, 144-60.

Source: <https://exaly.com/paper-pdf/25270721/citation-report.pdf>

Version: 2024-04-26

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
301	Expression of cytochrome P-450 3A in HT29-MTX cells and Caco-2 clone TC7. 1994 , 355, 247-50		48
300	Anaesthetic considerations in progressive familial intrahepatic cholestasis (Byler's disease). 1995 , 42, 1126-33		
299	Immunohistochemical localization of cytochrome P450 3A in human pulmonary carcinomas and normal bronchial tissue. 1995 , 103, 25-9		45
298	Immunohistochemical localization of cytochrome P450 2E1 in human pulmonary carcinoma and normal bronchial tissue. 1995 , 426, 243-7		13
297	Lack of presystemic metabolism of nifedipine in the rabbit. 1995 , 23, 567-80		2
296	The role of cytochrome P450 enzymes in hepatic and extrahepatic human drug toxicity. 1995 , 68, 385-424		112
295	The site of absorption in the small intestine determines diltiazem bioavailability in the rabbit. 1995 , 12, 1722-6		14
294	Metabolism of diltiazem in hepatic and extrahepatic tissues of rabbits: in vitro studies. 1995 , 12, 609-14		25
293	Extrahepatic metabolism of frusemide in anaesthetized rabbits. 1995 , 116, 2407-12		2
292	Comparison of effects of xenobiotics on extrahepatic and hepatic microsomal drug-metabolizing enzymes in mice. 1996 , 1, 123-30		3
291	In vivo induction of cytochrome P450 CYP3A expression in rat leukocytes using various inducers. 1996 , 51, 1579-82		23
290	The nifedipine gastrointestinal therapeutic system (GITS). Evaluation of pharmaceutical, pharmacokinetic and pharmacological properties. <i>Clinical Pharmacokinetics</i> , 1996 , 30, 28-51	6.2	69
289	Influence of diet and nutritional status on drug metabolism. <i>Clinical Pharmacokinetics</i> , 1996 , 31, 47-64	6.2	142
288	Glucuronidation of diflunisal in liver and kidney microsomes of rat and man. 1996 , 26, 123-31		21
287	Drug-drug interactions involving antidepressants: focus on venlafaxine. 1996 , 16, 37S-50S; discussion 50S-53S		73
286	Grapefruit juice alters the systemic bioavailability and cardiac repolarization of terfenadine in poor metabolizers of terfenadine. 1996 , 36, 345-51		47
285	Active secretion and enterocytic drug metabolism barriers to drug absorption. 1996 , 20, 99-112		78

284	Physicochemical and drug-delivery considerations for oral drug bioavailability. 1996 , 1, 461-473	117
283	Absorption and presystemic metabolism of selegiline hydrochloride at different regions in the gastrointestinal tract in healthy males. 1996 , 13, 1535-40	11
282	Deacetylation of diltiazem by several rabbit tissues. 1996 , 13, 1875-80	6
281	First-pass metabolism of diltiazem in anesthetized rabbits: role of extrahepatic organs. 1996 , 13, 124-8	14
280	The influence of food on the absorption and metabolism of drugs: an update. 1996 , 21, 201-11	39
279	Psychiatry, psychopharmacology and P-450s. 1996 , 11, 97-114	31
278	Dextromethorphan as an in vivo probe for the simultaneous determination of CYP2D6 and CYP3A activity. 1996 , 678, 113-28	58
277	Human cytochromes P450 expressed in Escherichia coli: production of specific antibodies. 1996 , 106, 207-19	42
276	Rifampin drastically reduces plasma concentrations and effects of oral midazolam. 1996 , 59, 7-13	200
275	Decreased intestinal CYP3A in celiac disease: reversal after successful gluten-free diet: a potential source of interindividual variability in first-pass drug metabolism. 1996 , 59, 41-6	51
274	Expression of cytochrome P 450 3A enzymes in human lung: a combined RT-PCR and immunohistochemical analysis of normal tissue and lung tumours. 1996 , 353, 207-12	46
273	Stereoselective sulphate conjugation of salbutamol by human lung and bronchial epithelial cells. 1996 , 41, 201-6	41
272	Modified Liquid Chromatographic Assay for Diltiazem and Metabolites in Human Plasma. 1996 , 19, 2385-2394	8
271	Drug Interactions Associated with Cytochrome P-450 Enzymes. 1996 , 4, 35-54	2
270	First-pass effect: significance of the intestine for absorption and metabolism. 1997 , 20, 329-44	45
269	Drug interactions with grapefruit juice. <i>Clinical Pharmacokinetics</i> , 1997 , 33, 103-21	6.2 185
268	Comparison of methodologies for evaluating regional intestinal permeability. 1997 , 423, 181-9	7
267	Pharmacokinetic drug interactions of new antidepressants: a review of the effects on the metabolism of other drugs. 1997 , 72, 835-47	111

266	Is my antihistamine safe?. 1997 , 2, 117-20		3
265	Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. <i>Clinical Pharmacokinetics</i> , 1997 , 32, 210-58	6.2	543
264	The lymphocyte transformation test for the diagnosis of drug allergy: sensitivity and specificity. 1997 , 27, 175-181		239
263	Observation of time-dependent and variable subject kinetics in a nifedipine gastrointestinal therapeutic system bioequivalency study. 1997 , 44, 247-254		5
262	Chronic, topical administration of 4-aminobiphenyl induces tissue-specific DNA adducts in mice. 1997 , 144, 325-31		12
261	Effect of route of administration of fluconazole on the interaction between fluconazole and midazolam. 1997 , 51, 415-9		79
260	Absorption of propranolol in humans following oral, jejunal, and ileal administration. 1998 , 15, 953-7		11
259	Effect of hepatic insufficiency on pharmacokinetics and drug dosing. 1998 , 20, 183-92		55
258	Gut wall metabolism of verapamil in older people: effects of rifampicin-mediated enzyme induction. 1998 , 45, 247-55		47
257	Cytochrome P450 in the brain: 2B or not 2B. 1998 , 19, 82-5		23
256	First-pass metabolism of cyclosporine A in human intestine: inhibition by diltiazem. 1998 , 30, 2545-6		5
255	Expression of intestinal drug-metabolizing enzymes in patients with chronic inflammatory bowel disease. 1998 , 59, 556-563		13
254	Drug interactions at the renal level. Implications for drug development. <i>Clinical Pharmacokinetics</i> , 1998 , 34, 375-404	6.2	54
253	Differential in vitro hepatic and intestinal metabolism of ifosfamide in the rat. 1998 , 28, 779-84		1
252	Xenobiotic metabolizing enzymes of the kidney. 1998 , 26, 18-25		77
251	Genes, oxidative stress, and the risk of chronic obstructive pulmonary disease. 1998 , 53 Suppl 2, S10-4		46
250	Clinically significant drug interactions. 1999 , 105, 193-5, 200, 205-6 passim		26
249	Sweat testing for cocaine, codeine and metabolites by gas chromatography-mass spectrometry. 1999 , 733, 247-64		71

248	The physiological and pharmacological roles of cytochrome P450 isoenzymes. 1999 , 54, 42-50	93
247	Chronopharmacology of intravenous and oral modified release verapamil. 1999 , 47, 413-9	20
246	Kinetic aspects of drug disposition in the lungs. 1999 , 26, 381-91	46
245	Gastrointestinal absorption of drugs: methods and studies. 1999 , 13, 154-68	194
244	Transport and metabolic characterization of Caco-2 cells expressing CYP3A4 and CYP3A4 plus oxidoreductase. 1999 , 16, 1352-9	47
243	Cytochrome P450 enzymes and drug metabolism--basic concepts and methods of assessment. 1999 , 19, 309-23	45
242	Drug metabolism and atypical antipsychotics. 1999 , 9, 301-9	65
241	CYP 3A proteins are expressed in human neutrophils and lymphocytes but are not induced by rifampicin. 1999 , 64, 643-53	26
240	Cytochrome P-450 3A4: regulation and role in drug metabolism. 1999 , 39, 1-17	1010
239	Relationships between steady state blood concentrations and cardiac output during intravenous infusions. 2000 , 21, 69-76	15
238	Comparative kinetics of metabolism of beclomethasone propionate esters in human lung homogenates and plasma. 2000 , 89, 1143-50	14
237	The effect of smoking on postoperative nausea and vomiting. 2000 , 55, 540-4	64
236	A comparison of the ontogeny of enterocytic and hepatic cytochromes P450 3A in the rat. 2000 , 60, 1601-10	35
235	The oral route for the administration of cytotoxic drugs: strategies to increase the efficiency and consistency of drug delivery. 2000 , 18, 231-41	32
234	Propofol inhibits renal cytochrome P450 activity and enflurane defluorination in vitro in hamsters. 2000 , 47, 680-6	8
233	Cytochrome P450 enzyme activity and protein expression in primary porcine enterocyte and hepatocyte cultures. 2000 , 30, 27-46	36
232	Regional and cellular distribution of CYP2D subfamily members in rat brain. 2000 , 30, 547-64	70
231	Characterization of cytochrome P450 enzymes involved in drug oxidations in mouse intestinal microsomes. 2000 , 30, 943-53	57

230	Assessment of potential mutagenic activities of a novel benzothiazole MAO-A inhibitor E2011 using <i>Salmonella typhimurium</i> YG1029. 2000 , 472, 163-9	6
229	Use of everted sacs of mouse small intestine as enzyme sources for the study of drug oxidation activities in vitro. 2000 , 30, 971-82	22
228	Strategies to overcome simultaneous P-glycoprotein mediated efflux and CYP3A4 mediated metabolism of drugs. 2001 , 2, 401-15	54
227	Interindividual variability in inhibition and induction of cytochrome P450 enzymes. 2001 , 41, 535-67	216
226	cDNA cloning and expression of a novel cytochrome p450 (cyp4f12) from human small intestine. 2001 , 280, 1135-41	66
225	Identification of human drug-metabolizing enzymes involved in the metabolism of SNI-2011. 2001 , 24, 1263-6	17
224	Enterocytic CYP3A4 in a paediatric population: developmental changes and the effect of coeliac disease and cystic fibrosis. 2001 , 51, 451-60	110
223	Biotransformation in vitro of the 22R and 22S epimers of budesonide by human liver, bronchus, colonic mucosa and skin. 2001 , 15, 47-54	5
222	Active secretion and enterocytic drug metabolism barriers to drug absorption. 2001 , 46, 89-102	238
221	Quantification and cellular localization of expression in human skin of genes encoding flavin-containing monooxygenases and cytochromes P450. 2001 , 62, 777-86	103
220	Induction of intestinal cytochrome P450 (CYP3A) by rifampicin in beagle dogs. 2001 , 134, 291-305	24
219	Cooperativity of alpha-naphthoflavone in cytochrome P450 3A-dependent drug oxidation activities in hepatic and intestinal microsomes from mouse and human. 2001 , 31, 265-75	26
218	Development of diltiazem deacetylase and demethylase activities during ontogeny in rabbit. 2001 , 31, 409-22	2
217	Species differences in the metabolism of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid in vitro: implications for prediction of metabolic interactions in vivo. 2002 , 32, 87-107	21
216	Sexual dimorphism and tissue specificity in the expression of CYP4F forms in Sprague Dawley rats. 2002 , 30, 1022-8	55
215	Metabolism. 2002 , 121-168	
214	Predicting pharmacokinetics and drug interactions in patients from in vitro and in vivo models: the experience with 5,6-dimethylxanthenone-4-acetic acid (DMXAA), an anti-cancer drug eliminated mainly by conjugation. 2002 , 34, 751-90	17
213	Downregulation of intestinal cytochrome p450 in chronic renal failure. 2002 , 13, 1579-85	86

212	Cytochrome P450 Expression in Rat Ocular Tissues and Its Induction by Phenobarbital.. 2002 , 48, 346-349	12
211	Metabolic extraction of nifedipine during absorption from the rat small intestine. 2002 , 17, 546-53	23
210	A mechanistic approach to understanding the factors affecting drug absorption: a review of fundamentals. 2002 , 42, 620-43	392
209	Drug-metabolizing activity of human and rat liver, lung, kidney and intestine slices. 2002 , 32, 349-62	69
208	Effects of DDT on paracetamol half-life in highly exposed mothers in Zimbabwe. 2002 , 134, 147-53	3
207	The mucosa of the small intestine: how clinically relevant as an organ of drug metabolism?. <i>Clinical Pharmacokinetics</i> , 2002 , 41, 235-53	6.2 172
206	Expression and regulation of xenobiotic-metabolizing cytochrome P450 (CYP) enzymes in human lung. 2002 , 32, 391-411	238
205	Differential induction of midazolam metabolism in the small intestine and liver by oral and intravenous dexamethasone pretreatment in rat. 2002 , 32, 975-84	24
204	Clinically significant drug interactions with antidepressants in the elderly. 2002 , 19, 299-320	101
203	Interacciones relevantes de los fármacos metabolizados por el sistema P-450. 2002 , 9, 432-439	
202	Cytochromes P450 and experimental models of drug metabolism. 2002 , 6, 189-98	217
201	Regional and cellular expression of CYP2D6 in human brain: higher levels in alcoholics. 2002 , 82, 1376-87	109
200	P-glycoprotein increases from proximal to distal regions of human small intestine. 2003 , 20, 1595-9	220
199	Hepatic drug metabolism and transport in patients with kidney disease. 2003 , 42, 906-25	89
198	Quinine 3-hydroxylation as a biomarker reaction for the activity of CYP3A4 in man. 2003 , 59, 23-8	22
197	Drug-drug interaction mediated by inhibition and induction of P-glycoprotein. 2003 , 55, 53-81	256
196	Pharmacokinetics in the newborn. 2003 , 55, 667-86	183
195	Timed-release formulation to avoid drug-drug interaction between diltiazem and midazolam. 2003 , 92, 790-7	22

194	Patch testing with carbamazepine and its main metabolite carbamazepine epoxide in cutaneous adverse drug reactions to carbamazepine. 2003 , 48, 137-9		18
193	Separation and detection methods for covalent drug-protein adducts. 2003 , 797, 63-90		44
192	Allelic variants of drug metabolizing enzymes as risk factors in psoriasis. 2003 , 120, 765-70		32
191	Pulmonary drug delivery. Part I: physiological factors affecting therapeutic effectiveness of aerosolized medications. 2003 , 56, 588-99		698
190	Role of P-glycoprotein in pharmacokinetics: clinical implications. <i>Clinical Pharmacokinetics</i> , 2003 , 42, 59-98		593
189	Strategies and molecular probes to investigate the role of cytochrome P450 in drug metabolism: focus on in vitro studies. <i>Clinical Pharmacokinetics</i> , 2003 , 42, 153-78	6.2	97
188	In vitro inhibitory effect of 1-aminobenzotriazole on drug oxidations catalyzed by human cytochrome P450 enzymes: a comparison with SKF-525A and ketoconazole. 2003 , 18, 287-95		87
187	Human uridine diphosphate-glucuronosyltransferase UGT2B7 conjugates mineralocorticoid and glucocorticoid metabolites. 2003 , 144, 2659-68		29
186	Dose-adjusted cyclosporine c2 in a patient with jejunoileal bypass as compared to seven other liver transplant recipients. 2003 , 25, 665-70		20
185	CYP2D in the brain. 2003 , 18, 337-49		46
184	Drug metabolism by cultured human hepatocytes: how far are we from the in vivo reality?. 2004 , 32, 101-10		6
183	Glucuronidation of the green tea catechins, (-)-epigallocatechin-3-gallate and (-)-epicatechin-3-gallate, by rat hepatic and intestinal microsomes. 2004 , 38, 1025-31		21
182	Identification of a novel mammary-restricted cytochrome P450, CYP4Z1, with overexpression in breast carcinoma. 2004 , 64, 2357-64		84
181	CYP2C and IL-6 expression in breast cancer. 2004 , 13, 28-34		30
180	The MDR1 (ABCB1) gene polymorphism and its clinical implications. <i>Clinical Pharmacokinetics</i> , 2004 , 43, 553-76	6.2	113
179	Effect of glucomannan and the dosage form on ethinylestradiol oral absorption in rabbits. 2004 , 70, 423-7		7
178	Absorption and metabolic extraction of diltiazem from the perfused rat small intestine. 2004 , 19, 430-7		6
177	Influence of rifampicin on the expression and function of human intestinal cytochrome P450 enzymes. 2005 , 59, 199-206		70

176	CAR and PXR: xenosensors of endocrine disrupters?. 2005 , 155, 111-28		225
175	A new technique for preparing precision-cut slices from small intestine and colon for drug biotransformation studies. 2005 , 51, 65-72		42
174	Human placenta: a human organ for developmental toxicology research and biomonitoring. 2005 , 26, 361-71		185
173	Development of a novel cytochrome p450 bioaffinity detection system coupled online to gradient reversed-phase high-performance liquid chromatography. 2005 , 10, 427-36		26
172	In vitro inhibitory effect of 1-aminobenzotriazole on drug oxidations in human liver microsomes: a comparison with SKF-525A. 2005 , 20, 351-7		34
171	Hepatic, extrahepatic, microsomal, and mitochondrial activation of the N-hydroxylated prodrugs benzamidoxime, guanoxabenz, and Ro 48-3656 ([1-[(2s)-2-[[4-[(hydroxyamino)iminomethyl]benzoyl]amino]-1-oxopropyl]-4-piperidinyl]oxy]-acetic acid). 2005 , 33, 1710-7		37
170	Cyp2D6 catalyzes 5-hydroxylation of 1-(2-pyrimidinyl)-piperazine, an active metabolite of several psychoactive drugs, in human liver microsomes. 2005 , 33, 203-8		9
169	Pharmacokinetics and metabolism of the plant cannabinoids, delta9-tetrahydrocannabinol, cannabidiol and cannabinol. 2005 , 657-90		159
168	Age, gender and region-specific differences in drug metabolising enzymes in rat ocular tissues. 2005 , 81, 710-5		20
167	Characterization of rat small intestinal and colon precision-cut slices as an in vitro system for drug metabolism and induction studies. 2005 , 33, 1613-20		48
166	Drug bioactivation, covalent binding to target proteins and toxicity relevance. 2005 , 37, 41-213		228
165	Role of cytochrome P450 activity in the fate of anticancer agents and in drug resistance: focus on tamoxifen, paclitaxel and imatinib metabolism. <i>Clinical Pharmacokinetics</i> , 2005 , 44, 349-66	6.2	93
164	Ontogeny of drug metabolizing enzymes in the neonate. 2005 , 10, 123-38		133
163	CYP3A4 and MDR Mediated Interactions in Drug Therapy. 2006 , 23, 125-163		7
162	Monitoring drug-protein interaction. 2006 , 365, 9-29		28
161	Hepatocyte cell lines: their use, scope and limitations in drug metabolism studies. 2006 , 2, 183-212		153
160	Liver Function and Inhaled Anesthetics. 2006 , 49, 1126		
159	Enzymatic characteristics of CYP3A5 and CYP3A4: a comparison of in vitro kinetic and drug-drug interaction patterns. 2006 , 36, 219-33		40

158	Approach to the prediction of the contribution of major cytochrome P450 enzymes to drug metabolism in the early drug-discovery stage. 2006 , 36, 671-83	52
157	Relative roles of CYP2C19 and CYP3A4/5 in midazolam 1Rhydroxylation. 2007 , 37, 592-603	14
156	CYP3A4 and CYP3A5 catalyse the conversion of the N-methyl-D-aspartate (NMDA) antagonist CJ-036878 to two novel dimers. 2007 , 37, 1408-1420	4
155	Polymorphic cytochrome P450 enzymes and post-marketing drug dosage revisions: clinical relevance to dermatologic therapies. 2007 , 26, 171-80	1
154	Effects of nonylphenol on the brain cytochrome P450 gene expression in F1 generation rats. 2007 , 89, 555-562	
153	Glucuronidation of thyroxine in human liver, jejunum, and kidney microsomes. 2007 , 35, 1642-8	51
152	Effects of ischemia-reperfusion on the absorption and esterase metabolism of diltiazem in rat intestine. 2007 , 80, 397-407	10
151	Principles of Drug Metabolism 3: Enzymes and Tissues. 2007 , 167-191	4
150	Induction of Cytochrome P450 CYP3A by St John's Wort in the Rat Liver and Intestine. 2007 , 2, 117863370700200	
149	Human cannabinoid pharmacokinetics. 2007 , 4, 1770-804	588
148	The intestine as a possible target for fumonisin toxicity. 2007 , 51, 925-31	90
147	Review article: The prevalence and clinical relevance of cytochrome P450 polymorphisms. 2007 , 26 Suppl 2, 211-9	83
146	Effect of atorvastatin on the intravenous and oral pharmacokinetics of verapamil in rats. 2008 , 29, 45-50	14
145	Orally efficacious thrombin inhibitors with cyanofluorophenylacetamide as the P2 motif. 2008 , 18, 2865-70	27
144	Expression of ovarian microsomal epoxide hydrolase and glutathione S-transferase during onset of VCD-induced ototoxicity in B6C3F(1) mice. 2008 , 230, 109-16	24
143	Identification of intestinal loss of a drug through physiologically based pharmacokinetic simulation of plasma concentration-time profiles. <i>Clinical Pharmacokinetics</i> , 2008 , 47, 245-59	6.2 37
142	The effects of rumen fluid on the in vitro aflatoxin binding capacity of different sequestering agents and in vivo release of the sequestered toxin. 2008 , 147, 292-309	32
141	Aflatoxins absorption in the gastro-intestinal tract and in the vaginal mucosa in lactating dairy cows. 2008 , 7, 53-63	37

140	Ethnic differences in psychotropic drug response and pharmacokinetics. 38-61	4
139	Hepatic cytochrome P450 enzyme alterations in humans with progressive stages of nonalcoholic fatty liver disease. 2009 , 37, 2087-94	220
138	Long-term effects of Panax ginseng on disposition of fexofenadine in rats in vivo. 2009 , 37, 657-67	28
137	Tissue distribution of CYP3A29 mRNA expression in Bama miniature pig by quantitative reverse transcriptase-polymerase chain reaction (RT-PCR). 2009 , 39, 423-9	21
136	[Drug interactions in geriatric medicine]. 2009 , 159, 462-9	4
135	Prediction of hepatic clearance in human from in vitro data for successful drug development. 2009 , 11, 262-76	153
134	Biotransformation of Xenobiotics. 2009 ,	6
133	Genetic polymorphism in CYP2E1: Population distribution of CYP2E1 activity. 2009 , 12, 362-88	75
132	Relationship between drug-induced interstitial lung diseases and cytochrome P450 polymorphisms. 2010 , 16, 496-502	13
131	Stereospecific reduction of the original anticancer drug oracin in rat extrahepatic tissues. 2003 , 55, 1003-11	1
130	Contribution of rat pulmonary metabolism to the elimination of lidocaine, midazolam, and nifedipine. 2010 , 38, 1183-8	17
129	Hepatocyte nuclear factor 4{alpha} regulates rifampicin-mediated induction of CYP2C genes in primary cultures of human hepatocytes. 2010 , 38, 591-9	34
128	ADME. 2010 , 145-200	3
127	Gene expression of CYP3A4, ABC-transporters (MDR1 and MRP1-MRP5) and hPXR in three different human colon carcinoma cell lines. 2003 , 55, 59-66	88
126	Ovarian Metabolism of Xenobiotics. 2010 , 457-467	
125	Metabolic Barrier of the Gastrointestinal Tract. 2010 , 53-75	2
124	A microfluidic approach for in vitro assessment of interorgan interactions in drug metabolism using intestinal and liver slices. 2010 , 10, 2778-86	162
123	Drug Metabolism in Gastrointestinal Tract. 2011 , 91-109	2

122	Cytochrome P450 polymorphisms and drug-induced interstitial lung disease. 2011 , 7, 1547-60	3
121	Efflux transporters- and cytochrome P-450-mediated interactions between drugs of abuse and antiretrovirals. 2011 , 88, 959-71	68
120	Inhibition of nifedipine metabolism in dogs by erythromycin: difference between the gut wall and the liver. 1997 , 49, 1205-10	5
119	Drug Metabolism and Toxicity in Chimeric Mice with Humanized Liver. 2011 , 57, 22-27	5
118	Toward managing chronic rejection after lung transplant: the fate and effects of inhaled cyclosporine in a complex environment. 2011 , 63, 88-109	10
117	Current understanding of drug disposition in kidney disease. 2012 , 52, 10S-22S	63
116	Intestinal cytochromes P450 regulating the intestinal microbiota and its probiotic profile. 2012 , 23,	23
115	Loss of orally administered drugs in GI tract. 2012 , 20, 331-44	92
114	Probe ADME and test hypotheses: a PATH beyond clearance in vitro-in vivo correlations in early drug discovery. 2012 , 8, 1131-55	10
113	Ontogeny of mammalian metabolizing enzymes in humans and animals used in toxicological studies. 2012 , 42, 323-57	47
112	Extrahepatic Drug-Metabolizing Enzymes and Their Significance. 2012 , 1	3
111	Reaction Phenotyping. 2012 , 189-212	1
110	Tyrosine kinase inhibitors and drug interactions: a review with practical recommendations. 2012 , 14, 94-101	24
109	Colonic bacterial metabolism of corticosteroids. 2013 , 457, 268-74	34
108	Pharmacokinetic evaluation of nabiximols for the treatment of multiple sclerosis pain. 2013 , 9, 1219-28	8
107	Considering CYP1A2 phenotype and genotype for optimizing the dose of olanzapine in the management of schizophrenia. 2013 , 9, 1115-37	24
106	From gut to kidney: transporting and metabolizing calcineurin-inhibitors in solid organ transplantation. 2013 , 452, 14-35	48
105	Inhalation Drug Delivery. 2013 , 1-14	5

104	Dispersive liquid-liquid microextraction of propranolol enantiomers from human plasma based on the solidification of a floating organic droplet. 2013 , 5, 701-10	11
103	The development of models for the evaluation of pulmonary drug disposition. 2013 , 9, 487-505	11
102	RNA-sequencing quantification of hepatic ontogeny and tissue distribution of mRNAs of phase II enzymes in mice. 2013 , 41, 844-57	33
101	Developmental pharmacokinetics in pediatric populations. 2014 , 19, 262-76	150
100	Principles of Drug Metabolism 3: Enzymes and Tissues. 2014 ,	1
99	Feasibility of 8-OHdG formation and hOGG1 induction in PBMCs for assessing oxidative DNA damage in the lung of COPD patients. 2014 , 19, 1183-90	16
98	The contribution of human OCT1, OCT3, and CYP3A4 to nitidine chloride-induced hepatocellular toxicity. 2014 , 42, 1227-34	28
97	Current knowledge on cannabinoids in oral fluid. 2014 , 6, 88-111	61
96	Dietary flavonoids modulate CYP2C to improve drug oral bioavailability and their qualitative/quantitative structure-activity relationship. 2014 , 16, 258-68	6
95	Cannabis and Drug-Facilitated Crimes. 2014 , 139-157	
94	Path (Probe ADME and Test Hypotheses): A Useful Approach Enabling Hypothesis-Driven ADME Optimization. 2014 , 63-88	
93	Targeting inhaled therapy beyond the lungs. 2014 , 88, 353-4	21
92	The role of particle physico-chemical properties in pulmonary drug delivery for tuberculosis therapy. 2014 , 31, 785-95	36
91	An evaluation of the latest in vitro tools for drug metabolism studies. 2014 , 10, 103-19	33
90	Inhibition of human cytochrome P450 enzymes by Bacopa monnieri standardized extract and constituents. 2014 , 19, 2588-601	26
89	Genetic Toxicology. 2014 , 1199-1230	
88	Resistance to cancer chemotherapy: failure in drug response from ADME to P-gp. 2015 , 15, 71	275
87	Distribution of (D)-Tetrahydrocannabinol and 11-Nor-9-Carboxy-(D)-Tetrahydrocannabinol Acid in Postmortem Biological Fluids and Tissues From Pilots Fatally Injured in Aviation Accidents. 2015 , 60, 942-9	9

86	Frog intestinal perfusion to evaluate drug permeability: application to p-gp and cyp3a4 substrates. 2015 , 6, 141	3
85	Discovery of imidazo[1,5-a]pyridines and -pyrimidines as potent and selective ROR α inverse agonists. 2015 , 25, 2907-12	49
84	Alterations in drug disposition in older adults. 2015 , 11, 491-508	64
83	[Drug-food interactions in internal medicine: What physicians should know?]. 2015 , 36, 530-9	11
82	Nicotine Increases Codeine Analgesia Through the Induction of Brain CYP2D and Central Activation of Codeine to Morphine. 2015 , 40, 1804-12	28
81	Drug Metabolism and Chronic Kidney Disease. 2015 , 674-681	3
80	Relation between some environmental pollutants and recurrent spontaneous abortion. 2016 , 9, S787-S794	3
79	Evaluation of the synergistic effect of , and on hepatic and intestinal drug metabolizing enzymes in rats. 2016 , 5, 372-382	3
78	The in vivo and in vitro phase I metabolism of FYL-67, a novel oxazolidinone antibacterial drug, studied by LC-MS/MS. 2016 , 8, 976-84	0
77	Evolution of Controlled Drug Delivery Systems. 2016 , 336-352	1
76	Metabolism and Drug-Drug Interaction in Pregnant Mother/Placenta/Fetus. 2016 , 1-16	1
75	Association of mitotane with chylomicrons and serum lipoproteins: practical implications for treatment of adrenocortical carcinoma. 2016 , 174, 343-53	14
74	HPLC-MS/MS method for the simultaneous determination of MB07133 and its metabolites, cytarabine and arabinofuranosyluracil, in rat plasma. 2016 , 120, 228-34	3
73	A comparison between genetically humanized and chimeric liver humanized mouse models for studies in drug metabolism and toxicity. 2016 , 21, 250-63	50
72	Oxidative stress and inflammation: liver responses and adaptations to acute and regular exercise. 2017 , 51, 222-236	41
71	Pharmacokinetic and pharmacodynamic alterations in older people with dementia. 2017 , 13, 651-668	38
70	Inducing rat brain CYP2D with nicotine increases the rate of codeine tolerance; predicting the rate of tolerance from acute analgesic response. 2017 , 145, 158-168	13
69	Profiles and Gender-Specifics of UDP-Glucuronosyltransferases and Sulfotransferases Expressions in the Major Metabolic Organs of Wild-Type and Efflux Transporter Knockout FVB Mice. 2017 , 14, 2967-2976	4

68	Is the clinical relevance of drug-food and drug-herb interactions limited to grapefruit juice and Saint-John's Wort?. 2017 , 118, 82-92	70
67	Genetically Humanized Animal Models. 2017 , 130-149	
66	Theophylline-7 β -Ribofuranoside (Theonosine), a New Theophylline Metabolite Generated in Human and Animal Lung Tissue. 2017 , 9,	0
65	Drug Metabolism in Preclinical Drug Development: A Survey of the Discovery Process, Toxicology, and Computational Tools. 2017 , 18, 556-565	52
64	Role of c-Jun-N-Terminal Kinase in Pregnane X Receptor-Mediated Induction of Human Cytochrome P4503A4 In Vitro. 2018 , 46, 397-404	11
63	Pharmacology of Inhaled Anesthetics. 2018 , 177-193	2
62	Role of Absorption, Distribution, Metabolism, Excretion, and Systemic Dose in Toxicology Testing. 2018 , 95-118	
61	Metabolic Barrier of the Gastrointestinal Tract. 2018 , 74-98	2
60	Ovarian Metabolism of Xenobiotics. 2018 , 495-506	
59	Layer-by-Layer Assembly of Nanosized Membrane Fractions for the Assessment of Cytochrome P450 Xenobiotic Metabolism. 2018 , 3, 12535-12544	7
58	Some Applications of Liquid Chromatography-Mass Spectrometry in the Biomedical Field: New Analytical Methodologies and Instrumental Approaches. 2018 , 79, 329-375	1
57	Vascularized Liver Organoids Generated Using Induced Hepatic Tissue and Dynamic Liver-Specific Microenvironment as a Drug Testing Platform. 2018 , 28, 1801954	58
56	Identification of the primary determining factor(s) governing the oral absorption of edaravone in rats. 2018 , 123, 312-320	4
55	Recent Advances in Electrochemical Biosensors Based on Enzyme Inhibition for Clinical and Pharmaceutical Applications. 2018 , 18,	78
54	Tumor response to irinotecan is associated with CYP3A5 expression in colorectal cancer. 2019 , 17, 3890-3898	5
53	Application of New Cellular and Microphysiological Systems to Drug Metabolism Optimization and Their Positioning Respective to In Silico Tools. 2019 , 24, 523-536	8
52	Hepatic CYP1A2 activity in liver tumors and the implications for preoperative volume-function analysis. 2019 , 316, G608-G614	6
51	Investigating the bioavailabilities of olerciamide A via the rat's hepatic, gastric and intestinal first-pass effect models. 2019 , 40, 112-120	2

50	Biological System Responses of Dairy Cows to Aflatoxin B1 Exposure Revealed with Metabolomic Changes in Multiple Biofluids. 2019 , 11,	23
49	Clinical Relevance of Medicinal Plants and Foods of Vegetal Origin on the Activity of Cytochrome P450. 2019 ,	1
48	Effects of Polymorphisms on Drug Addiction Risk Among the Chinese Han Population. 2019 , 7, 315	3
47	Metabolite identification of tanshinol borneol ester in rats by high-performance liquid chromatography combined with electrospray ionization quadrupole time-of-flight mass spectrometry. 2019 , 33, e4438	
46	Insight into pulmonary drug delivery: Mechanism of drug deposition to device characterization and regulatory requirements. 2019 , 54, 1-21	17
45	Human microbiota in aging and infection: A review. 2019 , 59, 537-545	16
44	Development and validation of probe drug cocktails for the characterization of CYP450-mediated metabolism by human heart microsomes. 2019 , 49, 187-199	6
43	Update efficacy of aerosol therapy with noninvasive ventilator approach (non-invasive ventilation and nasal high flow). 2020 , 59, 101922	10
42	Towards human organ perfusion models to elucidate drug pharmacokinetics in health and disease. 2020 , 52, 438-454	5
41	Human CYP2D6 Is Functional in Brain In Vivo: Evidence from Humanized CYP2D6 Transgenic Mice. 2020 , 57, 2509-2520	7
40	Drug-metabolizing enzymes: role in drug resistance in cancer. 2020 , 22, 1667-1680	26
39	Grafting of 3D Bioprinting to In Vitro Drug Screening: A Review. 2020 , 9, e1901773	36
38	Alginate-based drug oral targeting using bio-micro/nano encapsulation technologies. 2020 , 17, 1361-1376	13
37	Alterations in drug disposition in older adults: a focus on geriatric syndromes. 2021 , 17, 41-52	16
36	The Pharmacology of Cannabinoids. 2021 , 17-59	0
35	Clinical Pharmacokinetics of Cannabinoids and Potential Drug-Drug Interactions. 2021 , 1297, 27-42	3
34	The Role of Cannabinoids as Anticancer Agents in Pediatric Oncology. 2021 , 13,	2
33	Plant pharmacology: Insights into in-planta kinetic and dynamic processes of xenobiotics. 1-22	1

32	Evaluation of potential herb-drug interactions based on the effect of Suxiao Jiuxin Pill on CYP450 enzymes and transporters. 2021 , 280, 114408	0
31	Principles of Simulation. 2011 , 489-581	1
30	Mechanisms of Drug Interactions. 2001 , 13-38	3
29	Human Cannabinoid Pharmacokinetics and Interpretation of Cannabinoid Concentrations in Biological Fluids and Tissues. 2007 , 205-235	5
28	Mechanisms of Drug Interactions I: Absorption, Metabolism, and Excretion. 2011 , 11-41	1
27	Inhaled Anesthetics: Metabolism and Toxicity. 2010 , 633-666	7
26	Metabolic basis of drug interactions in the intensive care unit. 2000 , 22, 1-13	7
25	Oxybutynin enhances the metabolism of clomipramine and dextroprphan possibly by induction of a cytochrome P450 isoenzyme. 1999 , 19, 287-9	8
24	Diltiazem disposition and metabolism in recipients of renal transplants. 1998 , 20, 365-70	8
23	Effects of chronic administration of glucocorticoid on midazolam pharmacokinetics in humans. 1999 , 21, 507-13	18
22	The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. 1999 , 104, 147-53	693
21	Bioavailability Bloequivalence Assessments. 1998 , 429-467	4
20	Treating Depression: Potential Drug Interactions. 1997 , 27, 244-258	7
19	Polymorphism of glutathione S-transferase M1 and T1 genes and susceptibility to psoriasis disease: A study from North India. 2018 , 84, 39-44	7
18	Use of Toxicokinetics in Developmental and Reproductive Toxicology. 2005 , 571-597	
17	Use of toxicokinetics in developmental and reproductive toxicology. 2011 , 518-541	
16	Pharmacokinetic Considerations in the Toxicologic Evaluation of Xenobiotics. 1995 , 125-144	
15	Basic elements of applied pharmacology in the intensive care unit. 1998 , 111-123	

14	Chapter 2: Pharmacogenomics: Drug Exposure and Response. 2020 ,	
13	Interactions between the cytochrome P450 system and the second-generation antipsychotics. 2003 , 28, 99-112	92
12	Drug interactions: a primer for the gastroenterologist. 2012 , 8, 376-83	4
11	Acetaminophen (APAP, paracetamol) interferes with the first trimester human fetal ovary development in an ex vivo model.. 2022 ,	0
10	Osteoarthritis, Corticosteroids and Role of CYP Genes in COVID-19 Patients: A Mini Review. 2022 , 16, 18-25	
9	Farmacocinética de los medicamentos. 2022 , 26, 1-9	
8	Metabolism in the Gastrointestinal Tract: Relevance for Drug Development. 2021 , 71, S8-S10	
7	.. 2021 ,	2
6	Dermatokinetics: Advances and Experimental Models, Focus on Skin Metabolism.. 2022 ,	
5	Cytochrome P450 enzymes in the pediatric population: Connecting knowledge on P450 expression with pediatric pharmacokinetics. 2022 , 365-391	0
4	An HPLC-UV validated bioanalytical method for measurement of in vitro Phase 1 kinetics of Bynuclein binding bifunctional compounds. 1-45	0
3	Characterization of Novel Derivatives of MBQ-167, an inhibitor of the GTP-binding Proteins Rac/Cdc42.	0
2	Pharmacokinetics of Antimicrobials in Children with Emphasis on Challenges Faced by Low and Middle Income Countries, A Clinical Review. 2023 , 12, 17	1
1	Cannabis Pharmacogenomics: A Path to Personalized Medicine. 2023 , 45, 3479-3514	0